Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial
in 25,875 U.S. men and women investigating whether taking daily dietary supplements of
vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of
developing cancer, heart disease, and stroke in people who do not have a prior history of
these illnesses. This ancillary study is being conducted among participants in VITAL and will
examine whether vitamin D or omega-3 fatty acids affect risk of infection and plasma hCAP18
levels.
Phase:
N/A
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins